These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2291614)

  • 1. [Anticoagulants, platelet antiaggregants after aortocoronary bypass?].
    Nicolas G
    Ann Cardiol Angeiol (Paris); 1990 Dec; 39(10):613-6. PubMed ID: 2291614
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antithrombotic agents in coronary bypass surgery in The Netherlands].
    Galema TW; Verheugt FW
    Ned Tijdschr Geneeskd; 1990 Aug; 134(34):1632-6. PubMed ID: 2215703
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prevention of aortocoronary bypass occlusion].
    Cataldo G; Campolo L
    G Ital Cardiol; 1990 Aug; 20(8):766-72. PubMed ID: 2272426
    [No Abstract]   [Full Text] [Related]  

  • 4. Aspirin and mortality from coronary bypass surgery.
    Chesebro JH; Fuster V; Pugo FJ
    N Engl J Med; 2003 Mar; 348(11):1057-9; author reply 1057-9. PubMed ID: 12637618
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral anticoagulants or Aspirin study). Lancet 2000; 355: 346-51.
    Anand SS
    Vasc Med; 2001; 6(1):61. PubMed ID: 11358162
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antiplatelet drugs and prevention of aortocoronary bypass occlusion].
    Davì G; Botindari G; Catalano I; Strano A
    Cardiologia; 1988 Feb; 33(2):123-6. PubMed ID: 3282656
    [No Abstract]   [Full Text] [Related]  

  • 7. [Platelet antiaggregants in the treatment of vasculopathies].
    Honorato J; Montes-Jovellar B
    Angiologia; 1990; 42(1):1-10. PubMed ID: 2181892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Longterm treatment of POAD with anticoagulants and platelet inhibitors after endovascular procedures and vascular surgery: what is evidence based?].
    Landgraf H
    Hamostaseologie; 2006 Aug; 26(3):239-44; quiz 245-6. PubMed ID: 16906242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
    Meyer BJ
    Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of bypass occlusion].
    Kretschmer G
    Vasa Suppl; 1991; 33():56-8. PubMed ID: 1788763
    [No Abstract]   [Full Text] [Related]  

  • 11. [No benefit in the addition of dipyridamole to, nor of anticoagulants in comparison to, a low dose of acetylsalicylic acid (50 mg) in the prevention of venous transplant stenosis following coronary bypass surgery].
    Loeliger EA
    Ned Tijdschr Geneeskd; 1993 Dec; 137(51):2669. PubMed ID: 8278004
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anticoagulation in transitory ischemic attack after bypass surgery].
    Bruhn HD
    Dtsch Med Wochenschr; 1997 Feb; 122(7):210. PubMed ID: 9072493
    [No Abstract]   [Full Text] [Related]  

  • 13. The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
    D'Agate DJ; Patel S; Coppola JT; Ambrose JA
    J Invasive Cardiol; 2004 Sep; 16(9):500-3. PubMed ID: 15353833
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal medical management around the time of surgery.
    Voûte MT; Winkel TA; Poldermans D
    Heart; 2010 Nov; 96(22):1842-8. PubMed ID: 20965994
    [No Abstract]   [Full Text] [Related]  

  • 15. Aspirin and mortality from coronary bypass surgery.
    Karzai W; Priebe HJ
    N Engl J Med; 2003 Mar; 348(11):1057-9; author reply 1057-9. PubMed ID: 12638576
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anticoagulants and platelet antiaggregants: lessons of the last 20 years].
    De Moerloose P; Boehlen F
    Rev Med Suisse Romande; 1998 Jul; 118(7):641-4. PubMed ID: 9708021
    [No Abstract]   [Full Text] [Related]  

  • 17. [Maintaining patency of a coronary bypass: why doing it the hard way?].
    Verheugt FW
    Ned Tijdschr Geneeskd; 1993 Aug; 137(33):1645-6. PubMed ID: 8240546
    [No Abstract]   [Full Text] [Related]  

  • 18. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of surgical patients receiving anticoagulation and antiplatelet agents.
    Thachil J; Gatt A; Martlew V
    Br J Surg; 2008 Dec; 95(12):1437-48. PubMed ID: 18991253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets and platelet-inhibitor drugs in aortocoronary vein bypass operations.
    Chesebro JH; Fuster V
    Int J Cardiol; 1983; 2(5-6):511-6. PubMed ID: 6341260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.